Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immunotherapy will be given before surgery.

Trial Details

NCT ID
NCT06999980
Phase
PHASE2
Sponsor
Melanoma Institute Australia
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Ipilimumab 3mg/kg and nivolumab 1mg/kg
  • Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg
  • Nivolumab 480mg and relatlimab 160mg
  • Ipilimumab 1mg/kg and nivolumab 3mg/kg
  • Pembrolizumab 200 mg
Locations (sample)
  • Wollstonecraft, New South Wales, Australia|-33.8328,151.18981

Key Eligibility Criteria

  • Inclusion Criteria:
  • 1\. Written informed consent
  • 2\. Male or female patients who are at least 18 years of age on the day of signing informed consent.
  • 3\. Clinically detectable disease, and/or RECIST version 1.1 defined disease, and/or disease confirmed on PET imaging.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →